中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
19期
113-114
,共2页
西妥昔单抗%化学治疗%结直肠癌%肝转移
西妥昔單抗%化學治療%結直腸癌%肝轉移
서타석단항%화학치료%결직장암%간전이
cetuximab%chemotherapy%colorectal cancer%live metastases
目的：观察西妥昔单抗联合mFOLFOX6方案治疗结直肠癌肝转移的临床疗效。方法采用回顾性分析方法，选择2012年1月至2014年9月经组织病理学证实的结直肠癌肝转移患者40例，其中观察组（20例）采用西妥昔单抗联合mFOLFOX6化学治疗(简称化疗)方案治疗，对照组（20例）仅采用mFOLFOX6方案化疗。结果观察组完全缓解2例、部分缓解10例、稳定6例、进展2例，有效率60.00%；对照组分别为0例、7例、8例、5例，有效率为35.00%；观察组的临床有效率明显高于对照组（ P﹤0.05）。两组患者临床主要的毒副反应包括皮疹、恶心呕吐、腹泻、过敏反应、白细胞减少、神经毒性等，临床对症处理，均未影响治疗，两组差异无统计学意义（ P﹥0.05）。治疗后观察组生活质量评分为（25.48±4.84）分，低于对照组的（43.67±6.32）分（ P﹤0.05）。结论西妥昔单抗联合mFOLFOX6方案治疗结肠癌肝转移的临床疗效显著，值得临床推广。
目的：觀察西妥昔單抗聯閤mFOLFOX6方案治療結直腸癌肝轉移的臨床療效。方法採用迴顧性分析方法，選擇2012年1月至2014年9月經組織病理學證實的結直腸癌肝轉移患者40例，其中觀察組（20例）採用西妥昔單抗聯閤mFOLFOX6化學治療(簡稱化療)方案治療，對照組（20例）僅採用mFOLFOX6方案化療。結果觀察組完全緩解2例、部分緩解10例、穩定6例、進展2例，有效率60.00%；對照組分彆為0例、7例、8例、5例，有效率為35.00%；觀察組的臨床有效率明顯高于對照組（ P﹤0.05）。兩組患者臨床主要的毒副反應包括皮疹、噁心嘔吐、腹瀉、過敏反應、白細胞減少、神經毒性等，臨床對癥處理，均未影響治療，兩組差異無統計學意義（ P﹥0.05）。治療後觀察組生活質量評分為（25.48±4.84）分，低于對照組的（43.67±6.32）分（ P﹤0.05）。結論西妥昔單抗聯閤mFOLFOX6方案治療結腸癌肝轉移的臨床療效顯著，值得臨床推廣。
목적：관찰서타석단항연합mFOLFOX6방안치료결직장암간전이적림상료효。방법채용회고성분석방법，선택2012년1월지2014년9월경조직병이학증실적결직장암간전이환자40례，기중관찰조（20례）채용서타석단항연합mFOLFOX6화학치료(간칭화료)방안치료，대조조（20례）부채용mFOLFOX6방안화료。결과관찰조완전완해2례、부분완해10례、은정6례、진전2례，유효솔60.00%；대조조분별위0례、7례、8례、5례，유효솔위35.00%；관찰조적림상유효솔명현고우대조조（ P﹤0.05）。량조환자림상주요적독부반응포괄피진、악심구토、복사、과민반응、백세포감소、신경독성등，림상대증처리，균미영향치료，량조차이무통계학의의（ P﹥0.05）。치료후관찰조생활질량평분위（25.48±4.84）분，저우대조조적（43.67±6.32）분（ P﹤0.05）。결론서타석단항연합mFOLFOX6방안치료결장암간전이적림상료효현저，치득림상추엄。
Objective To observe cetuximab combined mFOLFOX6 scheme, the clinical curative effect of chemotherapy treatment for col-orectal cancer liver metastasis. Methods Used regression analysis method, in January 2012 to September 2014 histopathology confirmed 40 cases of patients with liver metastases from colorectal cancer, the observation group ( 20 cases ) with cetuximab combined mFOLFOX6 chemotherapy treatment;The control group ( 20 cases ) with mFOLFOX6 scheme only chemotherapy. Results The clinical curative effect, observation group ( 20 cases ) CR in 2 cases, PR for 10 cases, the SD for 6 cases, PD for 2 cases, RR was 60. 00%, the control group ( 20 cases ) CR 0 cases, PR in 7 cases, the SD for 8 cases, PD for 5 cases, RR was 35. 00%. The clinical effectiveness of observation group was obviously higher than that of control group ( P ﹤ 0. 05 ) . Two groups of patients with clinically main adverse reactions in-clude skin rashes, nausea, vomiting, liver function damage, neurotoxicity, hair loss, etc. Two groups of patients after clinical cure of adverse reaction, both influence for clinical treatment, two groups there was no statistically significant difference ( P ﹥ 0. 05 ) . Treatment of life score in both groups, observation group of life score was ( 25. 48 ± 4. 84 ) , the control group life score was ( 43. 67 ± 6. 32 ) , the quality of life of the differences between two groups was statistically significant ( P ﹤ 0. 05 ) . Conclusion cetuximab xidan resistance combined mFOLFOX6 scheme, the clinical curative effect of treatment for colon cancer liver metastasis is remarkable.
